论文部分内容阅读
目的:观察新型载药栓塞微球(Hepasphere)治疗肝脏肿瘤的安全性及其近期临床疗效.方法:12 例肝脏肿瘤患者在肝动脉化疗栓塞术中使用Hepasphere微球栓塞,对患者临床资料、影像随访资料、介入治疗的并发症和预后等情况进行总结和分析.采用mRESCIST标准,术后每月随访一次.12例肝脏肿瘤患者中,男性7例,女性5例,年龄43~69岁,中位年龄51岁.12例患者共行22次TACE.其中原发性肝癌5例,转移性肝癌7例(原发肿瘤为:结直肠癌3例,胆囊癌1例,神经内分泌癌1例,胰腺癌1例,胃癌1例).结果:12例患者随访7~12月,中位随访时间为9月,根据mRESCIST标准,3月疾病缓解率为50%,疾病控制率为83.3%,6月疾病缓解率为33.3%,疾病控制率为75%.所有患者均未出现胆汁漏并发感染、肝脓肿、腹腔出血、肿瘤破裂出血及消化道出血等严重并发症.少数患者术后当天腹痛较重,需盐酸哌替啶止痛,其他患者腹痛较轻.结论:应用新型栓塞微球(Hepasphere)治疗肝脏肿瘤的近期临床疗效及安全性均较好,远期效果仍需大量病例进一步观察.“,”Objective To evaluate the therapeutic results and safety of treatment for liver cancer with a new kind of microsphere. Methods 12 patients with liver cancer underwent TACE with Hepasphere microsphere. The clinical data, imaging follow-up data, complications of interventional treatment and prognosis were summarized and analyzed. Local response was evaluated with modified response evaluation criteria in solid tumors(mRECIST). There were 7 male, 5 female and the median age was 51 years. A total of 22 TACE procedures were performed in 12 patients. There were 5 patients with HCC and 7 patents with liver metastases(the primary tumor sites included: colorectal ca, neuroendocrine ca, gallbladder ca, pancreatic ca, gastric ca).Results The follow up period ranged from 7 months to 12 months(mid 9 months). The 3-month objective response rate was 50%, and disease control rate was 83.3%. The 6-month objective response rate was 33.3%, and disease control rate was 75%. In all the patients, no severe complications, such as bile leak complicated by infection, liver abscess, abdominal bleeding, tumor rupture bleeding and gastrointestinal bleeding occurred.Conclusion Chemoembolization with Hepasphere microsphere is a minimally invasive, safe and possibly effective palliative procedure in patients with liver cancer. Further investigation on a larger group of patients is required and will be continued.